Chinese pre-profit oncology drugs developer Zelgen has fixed the terms for its IPO on the Shanghai Stock Exchange targeting to raise 2.026 billion yuan ($294 million) while global venture capital firm GGV Capital has led a nearly $10 million Series pre-A round of financing in TAOS Data.
Register now to enjoy 3 free articles per month,
or log in to continue reading.
Stay informed with complimentary articles each month
Gain access to our exclusive newsletters delivered directly to your inbox
Be the first to know about all our summits!
Already a Subscriber? Log in
